PhagoMed (BioNTech R&D Austria after acquisition) has recently announced their acquisition by BioNTech SE.
The Austrian biotech startup is developing novel disease- targeted anti-bacterials. Their technology combats the urgent problem of antimicrobial resistance (AMR), which is being accelerated by the misuse of antibiotics. According to the WHO, AMR is one of the biggest threats to global health.
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected deep tech companies and help them boost their investment readiness and investor relations. 500 SMEs have been already accelerated. Join our community now to benefit from all our open services.
Launched in June 2019, the InvestHorizon Accelerator has selected 513 SMEs from 37 countries. Financed by the European Commission in association with Eureka, InvestHorizon aims to support deep tech SMEs, invite financial support, open access to global networks, and foster sustainable scalability.
This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.
We also use analytics services to help us understand where our audience is coming from. To opt-out click 'More information'.